Researching Effective Sleep Treatments (Project REST): A Partner-Assisted Intervention To Improve Adherence In Cognitive Behavioural Therapy For Insomnia
Funder
National Health and Medical Research Council
Funding Amount
$1,130,307.00
Summary
Insomnia is highly prevalent and predicts many other mental and physical problems. While very good behavioural treatments exist for insomnia, not everyone is able to comply with the difficult behaviour changes required to improve. Bed partners often influence sleep behaviours, and thus, can play a helpful role in the treatment of insomnia, if they are taught how. We will test the first intervention ever developed integrating the partner into insomnia treatment as a means of improving outcomes.
Acceptance And Commitment Therapy For Medication-resistant Psychosis: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$558,200.00
Summary
In spite of advances in medication, approximately one third of people with schizophrenia continue to experience distressing symptoms such as hearing voices and paranoia. Psychological 'talking treatments' are effective in helping people to cope with and be less distressed by these experiences. This study will be the first trial of a new psychological treatment, called Acceptance and Commitment Therapy, which may be more effective, briefer and more easily provided than existing approaches.
Modifying The Trajectory Of Insidious Late Life Cognitive Decline Using Computerised Cognitive Training
Funder
National Health and Medical Research Council
Funding Amount
$743,152.00
Summary
Supervised, group-based computerised cognitive training (CCT) is a safe and effective intervention to maintain cognition in healthy older adults. This project will examine the extent to which CCT can attenuate or even reverse the rate of decline in older people with previously documented cognitive decline, as well as strategies to maintain CCT effects in the long term.
Generating Stronger And Smarter T Cells For Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$310,332.00
Summary
White blood cells from cancer patients can be modified in the laboratory to react against tumours. These cells can then be given back to the patient, which can sometimes cause cancer regression. However, often the white blood cells lack strength, or they lack the ability to distinguish between tumour and normal tissues of the body. In this project we seek to make stronger and smarter white blood cells that can deliver a lethal hit against tumours without damaging essential organs of the body.
Increasing Physical Activity Among Young Children From Disadvantaged Communities: A Group Randomised Controlled Effectiveness Trial.
Funder
National Health and Medical Research Council
Funding Amount
$1,107,309.00
Summary
This project will evaluate the impact of a multi-level, multi-setting program to promote physical activity and movement skills among pre-school-aged children in disadvantaged communities. It will target the professional development of childcare educators and of parents. Childcare centres will be linked to the Early Start Facility at the University of Wollongong using state-of-the-art technology providing a unique opportunity to work with educators and parents in regional and remote areas.
Biomaterials For The Direct Reprograming Of Reactive Astrocytes Into Functional Neurons
Funder
National Health and Medical Research Council
Funding Amount
$630,500.00
Summary
We will employ peptide inspired hydrogel nanoscaffolds that can be injected into a brain lesion as a single injection to provide chemical and physical support for the surrounding cells. We will utilize various modifications to these materials to reprogram inflammatory cells into neurons, whilst also promoting the survival, maintenance and growth of existing neurons to encourage repair.
Efficacy Of Prism Adaptation For Recovery Of Brain Function In Unilateral Spatial Neglect
Funder
National Health and Medical Research Council
Funding Amount
$531,690.00
Summary
Damage to the brain’s attention network causes profound impairments of visual and sensory perception. These deficits are frequently long-lasting, and are a major factor in preventing patients from regaining functional independence. This project will use a combination of behavioural and brain imaging techniques to determine whether a promising new treatment involving visual retraining can improve function and reduce perceptual impairments after unilateral brain lesions.
Epilepsy is one of the most common chronic neurological disorders; it affects 1% of the world’s population, yet about 1 in 3 patients fail to achieve seizure control with current drugs. We will improve the properties of small molecules (drugs) that specifically target the GTPase activity of the enzyme dynamin, to reduce seizure effect in the brain by a novel mechanism. We will optimize and pre-clinically test these future chemical entities as potential anti-epileptic drugs.
Alpha-particles linked to recombinant antibodies targeting tumour cells have potential to effectively treat tumours while minimising normal tissue side effects. We will explore a novel alpha-particle therapy approach to solid tumours, by delivering 225Ac directly into tumour cells, or into cells that support the tumour (microenvironment). This approach will hopefully result in development of a new approach to treatment of cancers that are resistant to conventional therapies.
Determinants Of Sustained Virological Response After Discontinuation Of Long-term Nucleoside Analogue Therapy In Chronic Hepatitis B Patients
Funder
National Health and Medical Research Council
Funding Amount
$976,778.00
Summary
Guidelines currently recommend lifelong treatment for patients with chronic hepatitis B, with associated cost and risks of drug resistance and side effects. It has recently been suggested that up to 50% of patients may safely and successfully stop drug after long-term treatment. Our project will identify which patients can safely stop treatment, by performing detailed studies of the human immune system and the hepatitis B virus. This will be an important advance for patient care.